Observational studyImmunologic research2015
Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.
Observational study in Immunologic research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Association Between Metabolic Syndrome and Radiographic Changes in Psoriatic Arthritis: A Cohort Study.Arthritis care & research · 2025Observational
- Article
- Metabolic Syndrome in Psoriasis and Psoriatic Arthritis in a Mixed Race Population: Comparison of Their Prevalences.Psoriasis (Auckland, N.Z.) · 2024Article
- Article
- Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis.BMC pregnancy and childbirth · 2023Article
- Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.Frontiers in immunology · 2023Review
- Observational
- Acute joint swelling in psoriatic arthritis: Flare or "psout"-A 10-year-monocentric study on synovial fluid.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?Mediterranean journal of rheumatology · 2022Review
- Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement.Clinical rheumatology · 2022Article
- The cardiometabolic conditions of psoriatic disease.Frontiers in immunology · 2022Review
- Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study.Frontiers in medicine · 2022Article
- Article
- Psoriatic arthritis and the association with cardiometabolic disease: a narrative review.Therapeutic advances in musculoskeletal disease · 2021Review
- Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?Frontiers in medicine · 2021Review
- Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.ACR open rheumatology · 2020Article
- Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study.Rheumatology international · 2020Observational
- Obesity and its role in the management of rheumatoid and psoriatic arthritis.Clinical rheumatology · 2020Review
- Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.Journal of experimental pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to evaluate the influence of metabolic syndrome (MetS) on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients treated with anti-tumor necrosis factor (TNF)-α with a follow-up period of 24 months. A cohort of PsA patients was assessed at the University Federico II of Naples and at University of Padova. For the aim of the present study, patients' data were collected at baseline (T0), at 12 months (T1) and at 24 months (T2). Assessment of metabolic and disease activity parameters was performed at each visit. The NCEP-ACT III criteria were used to identify subjects with MetS and the MDA criteria to evaluate the disease activity. On the basis of the exclusion and inclusion criteria, 330 subjects were included in the study; 134 patients (40.7%) were classified as not having MetS and 196 (59.3%) as having MetS. An inverse association was found between presence of metabolic syndrome and the probability of achieving MDA. Univariate analysis indicated that patients with metabolic syndrome were less likely to achieve MDA than patients without metabolic syndrome (OR 0.45, p < 0.001). This inverse association remained statistically significant in the multivariate regression model (OR 0.56, p < 0.001). Metabolic syndrome is associated with a lower probability of achieving MDA in PsA patients in therapy with anti-TNF-α.
Indexed as
Identifiers
25395342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.